Saturday 17 October 2026
Export VIVS’s income statement to Excel — free account
VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.16
0.01
−5.88%
Follow VIVS
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 2 | — | — | — | 5 | 4 | 4 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
28.25 | 22.77 | 34.75 | 10.20 | 10.80 | — | 24.18 | 36.20 | 22.13 | 73.47 |
Altman Z-Score |
(71.71) | (34.37) | (80.27) | (22.18) | (6.66) | — | 2.55 | 5.74 | 4.83 | 22.56 |
Altman Z″-Score (non-manufacturers) |
(164.30) | (75.52) | (186.86) | (50.47) | (16.63) | — | (15.54) | (11.00) | (5.60) | 2.07 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(1.65) | (1.61) | (3.53) | (4.03) | (21.23) | — | (16.55) | (22.04) | (18.15) | (43.01) |
Beneish M-Score |
29.46 | (0.34) | (3.48) | — | — | — | (4.05) | (3.75) | (2.34) | (1.38) |
P/B ratio |
0.00 | 0.31 | 2.62 | 1.24 | 1.08 | — | 1.99 | 3.08 | 2.28 | 4.98 |
Price to Tangible BV |
0.00 | 0.31 | 2.62 | 1.24 | 1.08 | — | 1.99 | 3.08 | 2.28 | 4.98 |
EV/Sales |
(10.09) | (55.78) | 24.05 | 1.64 | 1.33 | — | 11.72 | 24.40 | 12.63 | 58.63 |
EV/EBITDA |
0.12 | 0.65 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.12 | 0.85 | (0.44) | (0.25) | (0.48) | — | (1.73) | (3.70) | (2.01) | (8.50) |
EV/FCF |
0.69 | 14.76 | (0.44) | (0.24) | (0.45) | — | (1.81) | (3.67) | (1.99) | (8.10) |
Quick Ratio |
2.18 | 3.04 | 1.58 | 4.40 | 20.73 | 51.82 | 15.18 | 9.91 | 9.61 | 10.55 |
Current Ratio |
2.38 | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 | 10.32 | 10.04 | 10.83 |
Net Debt/EBITDA |
0.45 | 0.92 | 0.20 | 0.92 | 2.53 | 2.23 | 1.35 | 1.39 | 1.29 | 1.68 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.00 | 0.06 | 0.07 | 0.08 | 0.06 |
Operating CF/Net income |
0.78 | 3.80 | 1.00 | 0.72 | 0.74 | 0.79 | 0.80 | 0.77 | 0.83 | 0.76 |
Capex/Depreciation |
0.00 | 33.79 | (0.15) | (1.35) | (2.88) | (9.59) | 0.65 | (0.08) | (0.23) | (1.17) |
Interest Coverage |
(957.25) | (1,261.60) | — | (39.06) | (1,434.87) | (1,121.73) | (36.15) | (38.69) | (73.79) | (194.82) |
| (294.75%) | (35.31%) | (155.00%) | (75.80%) | (32.99%) | (51.12%) | (59.46%) | (65.86%) | (65.08%) | (61.74%) | |
| (125.64%) | (23.70%) | (110.05%) | (64.39%) | (31.27%) | (49.23%) | (54.18%) | (58.89%) | (58.49%) | (56.23%) | |
ROIC |
0.00% | 0.00% | (1,346.96%) | 0.00% | (467.69%) | (574.03%) | 0.00% | 0.00% | (2,563.30%) | 0.00% |
Return on Tangible Assets |
(341.97%) | (28.23%) | (534.46%) | (120.87%) | (39.73%) | (44.21%) | (70.58%) | (72.64%) | (77.53%) | (61.10%) |
Average Days of Receivables |
2,914.43 | 76.04 | 110.50 | 149.95 | 0.00 | — | 18.45 | 65.89 | 81.52 | 55.83 |
Research and Development Expense of Revenue |
3,197.71% | 3,489.58% | 5,044.04% | 2,401.35% | 221.33% | 0.00% | 240.62% | 477.26% | 390.09% | 462.06% |
Selling, General and Administrative Expense of Revenue |
5,670.99% | 5,368.06% | 8,896.33% | 2,490.81% | 643.93% | 0.00% | 822.36% | 489.52% | 453.79% | 527.28% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
231.30% | 369.44% | 1,383.49% | 642.43% | 150.40% | 0.00% | 187.07% | 168.00% | 149.97% | 174.75% |
Graham Net Nets |
(0.50) | 2.43 | 0.13 | 0.63 | 0.81 | — | 0.50 | 0.31 | 0.41 | 0.19 |
Graham Number |
7.16 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(374.83%) | (75.71%) | (156.37%) | (89.99%) | (34.85%) | — | (36.72%) | (24.75%) | (34.75%) | (11.95%) |
Free Cash Flow Yield |
(51.61%) | (16.59%) | (156.77%) | (67.49%) | (27.30%) | — | (26.75%) | (18.34%) | (28.62%) | (9.86%) |
Revenue per Share |
0.05 | 0.10 | 0.14 | 0.51 | 2.07 | 0.00 | 4.07 | 6.43 | 10.30 | 10.39 |
Operating CF per Share |
(4.18) | (6.46) | (19.23) | (17.10) | (11.66) | (23.17) | (27.58) | (42.39) | (64.60) | (71.67) |
Capex per Share |
0.00 | 6.14 | (0.06) | (0.55) | (0.56) | (0.68) | 1.38 | (0.16) | (0.65) | (3.30) |
Free Cash Flow per Share |
(4.18) | (0.32) | (19.28) | (17.64) | (12.22) | (23.86) | (26.20) | (42.55) | (65.25) | (74.97) |
Cash per Share |
1.94 | 7.73 | 3.81 | 22.05 | 39.55 | 64.99 | 50.70 | 75.90 | 97.89 | 154.10 |
Shareholders Equity per Share |
(0.42) | 7.17 | 4.73 | 21.12 | 41.67 | 68.18 | 49.35 | 75.53 | 99.81 | 153.15 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.42) | 7.17 | 4.73 | 21.12 | 41.67 | 68.18 | 49.35 | 75.53 | 99.81 | 153.15 |
Free Cash Flow |
(10.83) | (0.47) | (14.69) | (12.80) | (8.86) | (13.72) | (14.13) | (20.45) | (29.15) | (30.53) |
Working Capital |
3.84 | 8.39 | 2.08 | 13.38 | 28.15 | 37.68 | 26.51 | 34.84 | 42.10 | 59.08 |
Capital Expenditures |
— | 8.99 | (0.04) | (0.40) | (0.41) | (0.39) | 0.75 | (0.08) | (0.29) | (1.34) |
Net Current Asset Value |
(1.86) | 7.97 | 1.19 | 12.06 | 26.45 | 37.68 | 26.51 | 34.25 | 41.52 | 58.27 |
EV/EBIT |
0.12 | 0.64 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | (62.41) | 0.39 | 1.07 | 0.27 | 0.00 | (0.34) | 0.02 | 0.06 | 0.32 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.04 | 0.63 | 0.42 | 0.32 | 0.21 | 0.11 | 0.00 | 0.53 | 0.45 | 0.30 |
Cash ROIC |
(275.85%) | (2.17%) | (226.01%) | (40.86%) | (15.05%) | (17.92%) | (26.18%) | (28.10%) | (33.01%) | (24.40%) |
Accounts Receivable Turnover |
0.24 | 4.57 | 1.18 | 2.81 | 0.00 | — | 6.57 | 3.90 | 5.50 | 9.34 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.79 | 0.41 | 0.08 | 0.49 | 0.88 | 1.26 | 0.98 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.86 | 0.72 | 1.48 | 2.16 |
Average Days of Payables |
0.00 | 120,012.00 | 0.00 | 412.34 | 1,066.73 | 2,501.59 | 801.22 | 475.56 | 164.43 | 447.09 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 307.13 | 371.06 | 298.38 | 209.99 |
Average Receivables |
0.54 | 0.03 | 0.09 | 0.13 | — | — | 0.33 | 0.79 | 0.84 | 0.45 |
Average Payables |
1.33 | 1.14 | 0.48 | 0.37 | 0.35 | 0.50 | 0.67 | 0.55 | 0.82 | 0.98 |
Average Inventory |
— | — | 0.29 | — | — | — | 0.38 | 0.67 | 0.70 | 0.44 |
Average Assets |
11.02 | 10.50 | 13.33 | 26.80 | 36.61 | 34.18 | 34.53 | 45.23 | 59.50 | 68.38 |
Average Common Equity |
4.70 | 7.05 | 9.47 | 22.77 | 34.70 | 32.91 | 31.46 | 40.44 | 53.47 | 62.27 |
Columns are period end dates